Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Agendia, Inc.
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
April 11, 2024
From
Agendia, Inc.
Via
Business Wire
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
March 20, 2024
From
Agendia, Inc.
Via
Business Wire
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
March 08, 2024
From
Agendia, Inc.
Via
Business Wire
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
February 01, 2024
From
Agendia, Inc.
Via
Business Wire
Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors
June 14, 2023
From
Agendia, Inc.
Via
Business Wire
Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
May 31, 2023
From
Agendia, Inc.
Via
Business Wire
Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
May 31, 2023
From
Agendia, Inc.
Via
Business Wire
Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
March 16, 2023
From
Agendia, Inc.
Via
Business Wire
Updated NCCN® Guidelines Recognize MammaPrint® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
February 13, 2023
From
Agendia, Inc.
Via
Business Wire
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
December 06, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
December 05, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
November 16, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
June 05, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
June 04, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
May 25, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Demonstrates Accessibility and Affordability of MammaPrint® and BluePrint® in Europe at ESMO Breast Cancer 2022
May 03, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
May 02, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy
March 15, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
February 07, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia to Provide First Digital MammaPrint Capability to Brazil
January 12, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
January 10, 2022
From
Agendia, Inc.
Via
Business Wire
Tickers
ILMN
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
January 06, 2022
From
Agendia, Inc.
Via
Business Wire
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint® as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
December 10, 2021
From
Agendia, Inc.
Via
Business Wire
Analysis Presented at SABCS 2021 Confirms MammaPrint® and BluePrint® Predict Outcomes Following Neoadjuvant Chemotherapy
December 09, 2021
From
Agendia, Inc.
Via
Business Wire
Agendia Presents Data at SABCS 2021 Showing MammaPrint® and BluePrint® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors
December 09, 2021
From
Agendia, Inc.
Via
Business Wire
Agendia’s MammaPrint® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial
June 07, 2021
From
Agendia, Inc.
Via
Business Wire
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
June 05, 2021
From
Agendia, Inc.
Via
Business Wire
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations
June 04, 2021
From
Agendia, Inc.
Via
Business Wire
ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes
June 04, 2021
From
Agendia, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.